Results 281 to 290 of about 227,991 (357)

The impact of systemic long‐term medications for the development of age‐related macular degeneration

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä   +3 more
wiley   +1 more source

Evaluating Diabetic Retinopathy Using Ultra-widefield Swept-Source Optical Coherence Tomography Angiography. [PDF]

open access: yesJ Vitreoretin Dis
Shah S   +12 more
europepmc   +1 more source

The impacts of high refractive errors on self‐reported visual function and visual concern

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To examine the association between refractive errors and self‐reported visual function and visual concern, considering self‐perceived present eyesight, concerns about vision, accomplishing less and limitations in daily activities in an eye‐healthy cohort.
Jens Riis Møller   +9 more
wiley   +1 more source

Association of treated neovascular AMD with disability and mood disorders: A longitudinal nationwide study

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To describe the associations of treated neovascular AMD with the risk of disability, falls, fractures and mood disorders in a large sample representative of the French population. Methods Analyses were based on 77 582 individuals belonging to the ‘Echantillon Généraliste des Bénéficiaires’, a 1/97 random sample of the French population,
Cécile Delcourt   +6 more
wiley   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy